Skip to main content

Table 6 Ongoing clinical trials phase 3 studies

From: COVID-19 pandemic crisis—a complete outline of SARS-CoV-2

Study title Conditions Interventions Locations
Randomized evaluation of COVID-19 therapy Severe acute respiratory syndrome Drugs: hydroxychloroquine, lopinavir/ritonavir, corticosteroid, azithromycin, tocilizumab Nuffield Department of Population Health, University of Oxford, Oxford, UK
Hydroxychloroquine and zinc with either azithromycin or doxycycline for treatment of COVID-19 in outpatient setting N COVID-19 Drugs: hydroxychloroquine, azithromycin, zinc sulfate, doxycycline St. Francis Hospital, Roslyn, NY, USA
Favipiravir in hospitalized COVID-19 patients COVID-19 Drugs: favipiravir, hydroxychloroquine Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran
Baricitinib therapy in COVID-19 COVID-19 pneumonia Drug: baricitinib 4 mg oral tablet Fabrizio Cantini, Prato, Tuscany, Italy
Treatment for COVID-19 in high-risk adult outpatients COVID-19 SARS-CoV-2 Drugs: ascorbic acid, hydroxychloroquine sulfate, azithromycin, folic acid • Boston University, Boston, MA, USA
• University of Washington Coordinating Center, Seattle, Washington, USA
• UW Virology Research Clinic, Seattle, WA, USA and 4 more
Convalescent plasma for hospitalized adults with COVID-19 respiratory illness (CONCOR-1) COVID-19 Other: convalescent plasma • Vancouver General Hospital, Vancouver, British Columbia, Canada
• Victoria General Hospital, Victoria, British Columbia, Canada
• London Health Sciences Centre—University Hospital, London, Ontario, Canada and 25 more
BCG vaccine for health care workers as defense against COVID-19 Coronavirus infection, Coronavirus as the cause of diseases classified elsewhere Biologicals: BCG vaccine, placebo vaccine • Harvard T.H. Chan School of Public Health, Boston, MA, USA
• Baylor College of Medicine, Houston, TX, USA
• MD Anderson Cancer Center, Houston, TX, USA and 4 more
Outcomes related to COVID-19 treated with hydroxychloroquine among in-patients with symptomatic disease Coronavirus acute respiratory infection
-SARS-CoV infection
• Drugs: hydroxychloroquine, placebo • Stanford University, Stanford, CA, USA
• University of Colorado Hospital, Aurora, CO, USA
• Denver Health Medical Center, Denver, CO, USA and 40 more
Treatment of COVID-19 patients with anti-interleukin drugs COVID-19 • Other: usual care
• Drugs: anakinra, siltuximab, tocilizumab
• University Hospital Saint-Pierre, Brussels, Belgium
• University Hospital Antwerp, Edegem, Belgium
• University Hospital Brussels, Jette, Belgium 13 more
Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with severe coronavirus disease (COVID-19) COVID-19 Drug: remdesivir • Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, CA, USA
• Alta Bates Summit Medical Center, Berkeley, CA, USA
• Mills-Peninsula Medical Center, Burlingame, CA, USA and180 more